Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Medytox Inc., Seoul, South Korea.
Dermatol Ther. 2021 Mar;34(2):e14787. doi: 10.1111/dth.14787. Epub 2021 Feb 9.
The long-term effectiveness and safety of hyaluronic acid fillers in mid-face volume restoration in Asians remain unclear. The objective of this study was to compare the long-term effectiveness and safety of Neuramis Volume Lidocaine (SHAPE-NVL) and Juvederm Voluma with Lidocaine (VYC-20L) in mid-face volume restoration in Asians. Overall, 88 Korean subjects with moderate-to-severe age-related mid-face volume deficit on the Mid-Face Volume Deficit Scale (MFVDS) received SHAPE-NVL on one side and VYC-20L on the contralateral side of the face. Of the 81 subjects who completed the 48-week primary study, 69 subjects were enrolled in an extension study lasting 104 weeks. MFVDS score and global aesthetic improvement were assessed at each visit. Response was defined as a ≥1-point reduction in MFVDS. At weeks 36 and 48, the responder rates for SHAPE-NVL were 81.93% and 80.72%, while those for VYC-20L were 85.54% and 81.92%, respectively. At the 104-week visit, the responder rates were 73.91% and 72.46% for SHAPE-NVL and VYC-20L, respectively. No subjects experienced any serious adverse events during the trial. SHAPE-NVL and VYC-20L showed comparable longevity and safety in mid-face volume restoration over 2 years in Asians. Both had durable effects for up to 2 years with minimal safety concerns.
透明质酸填充剂在亚洲人中中面部容量恢复的长期效果和安全性尚不清楚。本研究的目的是比较 Neuramis Volume Lidocaine(SHAPE-NVL)和 Juvederm Voluma with Lidocaine(VYC-20L)在亚洲人中中面部容量恢复中的长期效果和安全性。 共有 88 名韩国受试者在 Mid-Face Volume Deficit Scale(MFVDS)上存在中度至重度年龄相关性中面部容量不足,一侧接受 SHAPE-NVL,另一侧接受 VYC-20L。 在完成 48 周主要研究的 81 名受试者中,有 69 名受试者参加了持续 104 周的扩展研究。每次就诊时评估 MFVDS 评分和整体美学改善。反应定义为 MFVDS 降低≥1 分。在第 36 和 48 周,SHAPE-NVL 的应答率分别为 81.93%和 80.72%,而 VYC-20L 的应答率分别为 85.54%和 81.92%。在第 104 周时,SHAPE-NVL 和 VYC-20L 的应答率分别为 73.91%和 72.46%。试验过程中无受试者发生任何严重不良事件。 在亚洲人中,2 年以上的时间里,SHAPE-NVL 和 VYC-20L 在中面部体积恢复中表现出相当的持久性和安全性。两者都具有长达 2 年的持久效果,且安全性问题极小。